Abstract
Despite their rarity in incidence and prevalence, gastrointestinal stromal tumors (GISTs) have emerged as a distinct and noteworthy pathogenetic entity. The clinical management of GISTs has rapidly evolved due to the recent elucidation of their oncogenic signal transduction pathway and the introduction of molecular-targeted therapies. Successful management of GISTs requires a multidisciplinary approach firmly based on an accurate histopathologic diagnosis. In 2007, the Korean GIST study group published the first guideline for optimal diagnosis and treatment of GISTs in Korea. The second version of the guideline was published in 2010. Herein, we provide the results of relevant clinical studies for the purpose of further revision to the guideline. We expect this new guideline will enhance the accuracy of diagnosis, as performed by members of the Korean associate of physicians involved in GIST patient care, thus improving the efficacy of treatment.
| Original language | English |
|---|---|
| Pages (from-to) | 85-96 |
| Number of pages | 12 |
| Journal | Cancer Research and Treatment |
| Volume | 44 |
| Issue number | 2 |
| DOIs | |
| State | Published - Jun 2012 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Diagnosis
- Drug therapy
- Gastrointestinal stromal tumors
- Guideline
- Imatinib
- Molecular targeted therapy
- Sunitinib
- Surgery
Fingerprint
Dive into the research topics of 'Clinical practice guideline for accurate diagnosis and effective treatment of gastrointestinal stromal tumor in Korea'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver